A Single-center, Randomized, Blinded, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of One Dose of the SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in People Aged 18 Years and Older Who Had Received Two or Three Doses of Inactivated COVID-19 Vaccine
Latest Information Update: 06 Sep 2024
At a glance
- Drugs LVRNA 012 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors AIM Vaccine
- 01 Mar 2023 New trial record